Guidelines in Nuclear Medicine have been, and continue to be, developed by a number of organisations throughout the world. National regulations on the administration of radioactive substances and differences in clinical practice and service delivery mean that guidelines do not readily apply across regional and national boundaries. In Europe, the European Association of Nuclear Medicine (EANM) coordinating the development of guidelines, but recognises the need for national guidelines.
The BNMS does not wish to produce large, detailed guidelines covering the performance of specific diagnostic and therapeutic procedures. It does, however, wish to produce succinct Quality Guidelines which address the key aspects of procedures that affect the quality of the result. In this respect the BNMS guidelines seek to draw on published evidence to support quality statements.
The BNMS guidelines do not represent minimum standards. They do, however, contain elements that are mandatory (e.g. refer to regulations) or pseudo-mandatory. Other parts will be aspirational as far as some departments are concerned, but are nonetheless regarded as reasonable targets. They are intended to be dynamic documents.
The BNMS Clinical Procedure Guidelines were formally approved at the Annual General Meeting of the Society on 10 April 2001 and discussed on the following day at the Annual Conference. The guidelines are now in the public domain, they belong to you, not to BNMS Council. To let us know what you think (about specific guidelines or the process in general) please contact us.
The Organisational Audit section contains details of the Society's continuing programme which aims to audit every UK department.
The External Quality Assessment Schemes (EQAS) link is relevant to those carrying out non-imaging tests in Nuclear Medicine.
The Guidance on Staffing page in the BNMS Generic Guidelines section includes guidelines for the provision of radiopharmacy to nuclear medicine, guidelines for the provisions of physics support to nuclear medicine and the results of a survey of the role of the UK physicist in nuclear medicine.
BNMS guidelines for non-medical reporting of nuclear medicine investigations.
These guidelines are aimed at non-medical staff (e.g. physicists, radiographers and technologists) who intend to report on nuclear medicine examinations, or who already do so. Non-medical reporting should not be considered an alternative to the provision of suitably trained and experienced medical staff.
However it is recognised that there are local needs where the skills of non-medical staff will contribute to the provision of timely and accurate reports. The guidelines represent the outcome of a multidisciplinary working party and were approved at the Annual General Meeting in 2005.
Please note: At the time of writing these documents reflected current UK practice. However, practice does change and therefore some aspects of the guidance may be superceded before the document's review date.
NOTE : The Society is pleased to offer an advisory service to hospitals wishing to set up a Nuclear Medicine service. In the first instance, please contact
Dr Alp Notghi who will be delighted to advise and arrange for local Nuclear Medicine specialists to visit.
Dr Margaret Hall who is chair of the Professional Standards Committee
Reviewed November 2018
This guideline must be read in conjunction with the BNMS Generic Guidelines. The purpose of this guideline is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting the results of dynamic renal radionuclide studies. This guideline will assist individual departments in the development and formulation of their own local protocols.
BNMS Procedure Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localisation in Breast Carcinoma.
Reviewed November 2018 by Dr John Buscombe
The purpose of this guideline is to assist practitioners in recommending, performing, interpreting and reporting sentinel node imaging for identifying sentinel nodes for excisional biopsy in patients with breast carcinoma.